Big Pharma Can Rival Big Software · a16z News
Business, Finance & Industries · Nov 13, 2026
Pharma’s concentrated, patent-protected revenue model means a single successful drug can generate software-scale returns over many years, making AI valuable if it improves the odds and speed of developing commercially differentiated medicines.
Big Pharma Can Rival Big Software · a16z News
Business, Finance & Industries · Nov 13, 2026
If AI makes drug discovery reliably repeatable, investors may begin valuing pharmaceutical discovery platforms and infrastructure—not just approved drugs and late-stage assets—potentially enabling more predictable growth, diversified pipelines, and less dependence on blockbuster franchises threatened by patent expirations.
Big Pharma Can Rival Big Software · a16z News
Science, Technology & Innovation · Nov 13, 2026
The Bio × AI market is developing around both pharma-enabling platforms and vertically integrated drug developers, with commercial partnerships signaling growing confidence in molecular-design tools while scarce biological data and the need for wet-lab and clinical validation keep clinical translation as the ultimate test.
Big Pharma Can Rival Big Software · a16z News
Business, Finance & Industries · Nov 13, 2026
AI could materially reduce drug-development costs by increasing clinical success rates and shortening approval timelines across target selection, candidate screening, trial execution, and regulatory work. Given that fewer than 5% of candidates succeed, development averages 13 years, and successful drugs cost nearly $2 billion including failures, AI may make more therapies economically viable, increase the number of development attempts, and expand—not replace—wet-lab experimentation, benefiting CROs, lab automation, and specialized data providers.